Conavi Medical Provides Shareholder Update and 2025 Outlook - U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026- Evolving medical guidelines position next-generation Novasight...

Conavi Medical and Minnetronix Medical Publish In-Depth Collaboration Review TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing,...

Conavi Medical Announces Grant of Stock Options TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”) announced that its board of directors (the “Board”) has approved grants of stock...

Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights – Completed US$7.7 million financing and reverse takeover to take Company public – Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million...